SCHEMBL5444128

SCHEMBL5444128

Cc1ccccc1CCSc1c(C=NO)c(C(F)(F)F)nn1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 9/20 0.48
LMNA P02545 3/20 0.48
RECQL P46063 2/20 0.48
PRNP P04156 1/20 0.48
ALDH1A1 P00352 2/20 0.47
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 5/20 0.42
CYP2C9 P11712 4/20 0.42
CYP2C19 P33261 4/20 0.42
POLB P06746 2/20 0.42
CYP3A4 P08684 2/20 0.42
SMN1; SMN2 Q16637 4/20 0.39
NPSR1 Q6W5P4 3/20 0.39
ADAMTS5 Q9UNA0 3/20 0.39
USP2 O75604 1/20 0.36
CYP2D6 P10635 2/20 0.36
MEN1 O00255 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ADAMTS4 O75173 2/20 0.33
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5444123 1.00 HTT (0.48) HTTLMNARECQLPRNPALDH1A1
SCHEMBL14466994 0.89 HTT (0.56) HTTLMNARECQLPRNPALDH1A1
SCHEMBL5336838 0.87 HTT (0.50) HTTLMNARECQLPRNPALDH1A1
SCHEMBL5336833 0.87 HTT (0.50) HTTLMNARECQLPRNPALDH1A1
SCHEMBL5337340 0.80 HTT (0.71) HTTLMNARECQLPRNPALDH1A1
SCHEMBL5337333 0.80 HTT (0.71) HTTLMNARECQLPRNPALDH1A1
SCHEMBL14467350 0.79 HTT (0.61) HTTLMNARECQLPRNPALDH1A1
SCHEMBL5477079 0.79 HTT (0.61) HTTLMNARECQLPRNPALDH1A1
SCHEMBL5335069 0.75 HTT (0.59) HTTLMNARECQLPRNPALDH1A1
SCHEMBL5335075 0.75 HTT (0.59) HTTLMNARECQLPRNPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007084868-A2 TREATMENT OF DISORDERS BY ACTIVATION OF THE UNFOLDED PROTEIN RESPONSE KALYPSYS, INC. (US) 2007-07-26 WO disclosed